Webinar

Live Stream: Out of the Shadows: Starting the Conversation About Bowel Urgency in Patients with Crohn’s Disease

Launch Date
01/25/2024 at 03:00 pm EST
Credit Amount
1.5
Credit Expires
01/28/2024

Faculty

Marla Dubinsky, MD
Moderator
Professor of Pediatrics and Medicine 
Co-Director, Susan and Leonard Feinstein IBD Clinical Center 
Director, Marie and Barry Lipman IBD Preconception and Pregnancy Clinic 
Icahn School of Medicine, Mount Sinai New York 
Chief, Division of Pediatric GI and Nutrition 
Mount Sinai Kravis Children’s Hospital
New York, NY
Millie D. Long, MD, MPH
Professor of Medicine 
Vice-Chief for Education
Director, Gastroenterology and Hepatology Fellowship Program
Division of Gastroenterology and Hepatology 
University of North Carolina 
Chapel Hill, NC 
Tauseef Ali, MD, FACP, FACG, AGAF
Medical Director 
SSM Health Crohn's and Colitis Center 
Medical Executive Director 
SSM Health Digestive Care 
Clinical Associate Professor 
University of Oklahoma Health Sciences Center 
Oklahoma City, OK
Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Studies demonstrate that approximately 65%-82% of patients with Crohn’s disease (CD) report at least some degree of bowel urgency, but this symptom is largely underrecognized by gastroenterologists and health care professionals (HCPs) caring for patients with inflammatory bowel disease (IBD). There is a lack of awareness and appreciation of the impact of bowel urgency in patients with CD as it is most commonly associated with ulcerative colitis. Bowel urgency in patients with CD results in emotional and social stress, leading to stigma, feelings of isolation, and impacting all aspects of daily life for patients. Bowel urgency is not widely incorporated into clinical assessment indices or clinical trial endpoints for CD, despite being a pivotal symptom influencing patient health-related QoL (HRQoL) and a potential indicator of uncontrolled intestinal inflammation.

In this CMEO Outfitters live-streamed symposium, expert faculty will discuss recognizing the frequency of bowel urgency in patients with CD and the impact on patient QoL, incorporating assessments for bowel urgency through symptom evaluation, and engaging patients in open communication about their bowel urgency as part of shared decision-making in order to improve clinical outcomes, and the faculty will also review real-world patient cases.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Recognize the frequency of bowel urgency in patients with CD and the impact on patient quality of life.
  • Incorporate assessments for bowel urgency as part of thorough symptom evaluation for patients with CD.
  • Engage patients in open communication about their bowel urgency as part of shared decision-making in order to improve clinical outcomes.

Financial Support

This activity is supported by an education grant from Lilly.

Target Audience

Gastroenterologists, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 1.5

This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME) 1.5

CME Outfitters, LLC, designates this Live Activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.5

This activity is designated for 1.50 contact hours.

Pharmacists (ACPE) 1.5

This application-based activity is approved for 1.50 contact hours ( 0.15 CEUs) of continuing pharmacy credit ( JA0007185-0000-24-005-L01-P ).

PAs (AAPA) 1.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until 01/27/2025. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Dubinsky reports the following financial relationships:

Advisory Board and Consultant: AbbVie Inc.; Abivax; AstraZeneca; Bristol Myers Squibb Company; Janssen Biotech, Inc.; Lilly; Merck & Co., Inc; Pfizer Inc.; Prometheus Biosciences; and Prometheus Laboratories; Takeda Pharmaceuticals U.S.A., Inc.

Dr. Ali reports the following financial relationships:

Advisory Board: AbbVie Inc. and Janssen Pharmaceuticals, Inc.
Consultant: AbbVie Inc.; Boehringer Ingelheim; Fresenius Kabi USA; and E.R. Squibb & Sons, L.L.C.
Research Support: AbbVie Inc.; Arena Pharmaceuticals; AstraZeneca; and Celgene Corporation
Speakers Bureau: AbbVie Inc.; E.R. Squibb & Sons, L.L.C.;
Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Dr. Long reports the following financial relationships:

Consultant: AbbVie Inc.; Bristol Myers Squibb Company; Intercept Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc.; Prometheus Biosciences, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Target RWE
Research Support: Lilly; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

 

The following individuals have no financial relationships to disclose:

Rebecca Vargas-Jackson, MD  (Peer Reviewer)
Shirley Michelle Franks, MSN, APRN, FNP-BC (Peer Reviewer)
Susan Perry (Planning Committee)
Kasey Brandt, PharmD (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

MMS-136-012524-11

Live Stream: Out of the Shadows: Starting the Conversation About Bowel Urgency in Patients with Crohn’s Disease
Event Date: 01/25/2024 at 03:00 pm EST
Begin